Granahan Investment Management’s NeoGenomics NEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-244,924
| Closed | -$2.98M | – | 184 |
|
|
2022
Q1 | $2.98M | Sell |
244,924
-276,117
| -53% | -$5.81M | 0.07% | 157 |
|
|
2021
Q4 | $17.8M | Buy |
521,041
+190,169
| +57% | +$7.45M | 0.37% | 74 |
|
|
2021
Q3 | $16M | Sell |
330,872
-55,315
| -14% | -$2.56M | 0.3% | 82 |
|
|
2021
Q2 | $17.4M | Buy |
386,187
+26,931
| +7% | +$1.19M | 0.33% | 73 |
|
|
2021
Q1 | $17.3M | Sell |
359,256
-102,484
| -22% | -$5.34M | 0.37% | 63 |
|
|
2020
Q4 | $24.9M | Sell |
461,740
-107,117
| -19% | -$4.84M | 0.56% | 46 |
|
|
2020
Q3 | $21M | Sell |
568,857
-57,862
| -9% | -$2.15M | 0.71% | 41 |
|
|
2020
Q2 | $19.4M | Buy |
626,719
+10,633
| +2% | +$295K | 0.7% | 41 |
|
|
2020
Q1 | $17M | Sell |
616,086
-365,262
| -37% | -$10.9M | 0.92% | 29 |
|
|
2019
Q4 | $28.7M | Sell |
981,348
-3,870
| -0.4% | -$92.2K | 1.32% | 19 |
|
|
2019
Q3 | $18.8M | Buy |
985,218
+47,356
| +5% | +$1.11M | 1.04% | 25 |
|
|
2019
Q2 | $20.6M | Sell |
937,862
-56,042
| -6% | -$1.23M | 1.02% | 29 |
|
|
2019
Q1 | $20.3M | Sell |
993,904
-196,794
| -17% | -$3.42M | 1.09% | 24 |
|
|
2018
Q4 | $15M | Sell |
1,190,698
-56,629
| -5% | -$844K | 1.06% | 29 |
|
|
2018
Q3 | $19.1M | Buy |
1,247,327
+34,313
| +3% | +$474K | 1.04% | 29 |
|
|
2018
Q2 | $15.9M | Buy |
1,213,014
+97,040
| +9% | +$1.07M | 0.96% | 27 |
|
|
2018
Q1 | $9.11M | Buy |
1,115,974
+14,321
| +1% | +$116K | 0.66% | 49 |
|
|
2017
Q4 | $9.76M | Buy |
1,101,653
+36,571
| +3% | +$337K | 0.77% | 41 |
|
|
2017
Q3 | $11.9M | Buy |
1,065,082
+53,958
| +5% | +$525K | 0.99% | 26 |
|
|
2017
Q2 | $9.06M | Sell |
1,011,124
-296,755
| -23% | -$2.36M | 0.84% | 34 |
|
|
2017
Q1 | $10.3M | Sell |
1,307,879
-1,038,226
| -44% | -$8.46M | 1.04% | 27 |
|
|
2016
Q4 | $20.1M | Buy |
2,346,105
+303,600
| +15% | +$2.6M | 0.69% | 54 |
|
|
2016
Q3 | $16.8M | Buy |
2,042,505
+39,700
| +2% | +$333K | 0.55% | 73 |
|
|
2016
Q2 | $16.1M | Buy |
2,002,805
+221,670
| +12% | +$1.78M | 0.59% | 66 |
|
|
2016
Q1 | $12M | Sell |
1,781,135
-59,840
| -3% | -$394K | 0.44% | 85 |
|
|
2015
Q4 | $14.5M | Buy |
1,840,975
+20,258
| +1% | +$148K | 0.5% | 73 |
|
|
2015
Q3 | $10.4M | Sell |
1,820,717
-120,212
| -6% | -$744K | 0.32% | 112 |
|
|
2015
Q2 | $10.5M | Buy |
1,940,929
+715,950
| +58% | +$3.69M | 0.3% | 121 |
|
|
2015
Q1 | $5.72M | Sell |
1,224,979
-43,827
| -3% | -$191K | 0.16% | 169 |
|
|
2014
Q4 | $5.29M | Sell |
1,268,806
-68,309
| -5% | -$314K | 0.15% | 160 |
|
|
2014
Q3 | $6.97M | Buy |
1,337,115
+61,222
| +5% | +$314K | 0.22% | 145 |
|
|
2014
Q2 | $4.24M | Buy |
1,275,893
+8,232
| +0.6% | +$27.4K | 0.12% | 171 |
|
|
2014
Q1 | $4.4M | Buy |
1,267,661
+236,530
| +23% | +$886K | 0.12% | 178 |
|
|
2013
Q4 | $3.73M | Buy |
1,031,131
+641,901
| +165% | +$2.23M | 0.1% | 181 |
|
|
2013
Q3 | $1.17M | Buy |
389,230
+147,280
| +61% | +$415K | 0.03% | 204 |
|
|
2013
Q2 | $963K | Buy |
+241,950
| New | +$923K | 0.03% | 215 |
|
Other funds holding NEO
FLAM
Granahan Investment Management's NEO Position: Q2 2022 in Review
Granahan Investment Management sold out of NeoGenomics (NEO) in Q2 2022, closing a stake of 244,924 shares — an estimated $2.98M sold.
Granahan Investment Management first reported a position in NEO in Q2 2013 and held it in 36 quarters. The position peaked at $28.7M in Q4 2019. 240 funds tracked by Wall St. Rank hold NEO as of Q2 2022.
- Granahan Investment Management reported no remaining NeoGenomics position as of Q2 2022 after selling out during the quarter.
- Granahan Investment Management sold 244,924 NeoGenomics shares in Q2 2022, an estimated $2.98M.
- Granahan Investment Management first reported a position in NeoGenomics in Q2 2013 and held it in 36 quarters.
- Granahan Investment Management's NeoGenomics position peaked at $28.7M in Q4 2019.
- 240 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2022.
Based on Granahan Investment Management's 13F filing for Q2 2022, filed 15 Aug 2022.